Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2010
10/26/2010US7820168 Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
10/26/2010US7820167 IL1-β: a new target for myeloma therapy
10/26/2010US7820166 Potent T cell modulating molecules
10/26/2010US7820164 antibody binds target tissue and conjugate carrying epitope (haptens); monoclonal antibody or fragment thereof binds to a colon-specific antigen-p mucin (CSAp) antigen - the Mu-9 epitope; DNA sequence; colon cancer
10/26/2010US7820162 Methods for chemically synthesizing immunoglobulin chimeric proteins
10/26/2010US7820161 Treatment of autoimmune diseases
10/26/2010US7820160 Midkine inhibitory compositions for the treatment of angiostenosis
10/26/2010US7820159 Using epidermal growth factor receptor as tool in identifying modulators for prevention and treatment of cell proliferative disorders
10/26/2010CA2579391C Anti-a33 antibody
10/26/2010CA2443840C Cripto blocking antibodies and uses thereof
10/26/2010CA2351887C Psca: prostate stem cell antigen and uses thereof
10/26/2010CA2330639C Method for producing a specific antiserum against the universal tumorous antigen and method for diagnosing malignant tumours using said antiserum
10/26/2010CA2326501C Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
10/26/2010CA2249409C Iga1 protease fragment as carrier peptide
10/26/2010CA2197717C Mycobacteria functional screening and/or expression vectors
10/26/2010CA2195752C Oligomeric carrier molecules with defined incorporated marker groups andhaptens
10/21/2010WO2010121266A1 Targeted detection of dysplasia in barrett's esophagus with a novel fluorescence-labeled polypeptide
10/21/2010WO2010121208A2 New methods of making an antibody and compositions thereof
10/21/2010WO2010121180A1 Combination immunotherapy compositions against cancer and methods
10/21/2010WO2010121141A1 Compositions and methods to treat acute myelogenous leukemia
10/21/2010WO2010121093A2 Humanized antibody compositions and methods for binding lysophosphatidic acid
10/21/2010WO2010120921A1 Meningococcal and pneumococcal conjugate vaccine and method of using same
10/21/2010WO2010120874A2 Chimeric therapeutics, compositions, and methods for using same
10/21/2010WO2010120766A1 Engineered botulinum neurotoxin
10/21/2010WO2010120726A1 Treatment of inflammatory diseases by inhibiting cold- inducible rna-binding protein (cirp)
10/21/2010WO2010120599A2 Compositions and methods for treating cancer
10/21/2010WO2010120592A1 Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
10/21/2010WO2010120566A2 METHODS FOR TREATING IgE-MEDIATED DISORDER
10/21/2010WO2010120561A1 Anti-fcrh5 antibodies and immunoconjugates and methods of use
10/21/2010WO2010120541A2 Compositions and methods for modulating the activity of complement regulatory proteins on target cells
10/21/2010WO2010120506A1 Combination treatment of cancer with cetuximab and tetrac
10/21/2010WO2010120271A1 Use of vectors expressing intracellular polynucleotide binding proteins as adjuvants
10/21/2010WO2010120195A1 Macrocyclic lactone combination compositions, vaccines and methods for producing same
10/21/2010WO2010119991A2 Novel method of treating cancer
10/21/2010WO2010119704A1 Antibodies that specifically bind to a beta oligomers and use thereof
10/21/2010WO2010119691A1 Diagnosis and treatment of cancer using anti-tmprss11e antibody
10/21/2010WO2010119343A2 Compositions for immunising against staphylococcus aureus
10/21/2010WO2010119306A1 Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
10/21/2010WO2010119245A2 Vaccine
10/21/2010WO2010119112A1 Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
10/21/2010WO2010118890A1 B-lymphocyte targeting agents for use in a method for the treatment of a disease
10/21/2010WO2010118547A1 Protein for the immunocastration for mammals
10/21/2010WO2010118522A1 Antibodies against prostate specific membrane antigen
10/21/2010WO2010099472A3 Spanx-b polypeptides and their use
10/21/2010WO2010099139A3 Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
10/21/2010WO2010087594A3 Cd93 or use of soluble fragment thereof
10/21/2010WO2010072740A3 TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
10/21/2010WO2010062742A3 Methods for freparation and use of marrow infiltrating lymphocytes (mils)
10/21/2010WO2010055366A3 Anti-human il-21 monoclonal antibodies
10/21/2010WO2010047509A3 Anti-dr5 antibody with improved affinity and stability, and composition for cancer prevention or treatment including same
10/21/2010WO2010026602A3 Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis
10/21/2010WO2009094717A3 A method of inducing tolerance to an allergen
10/21/2010US20100267936 PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES
10/21/2010US20100267816 Human anti-amyloid beta peptide antibody and fragment of said antibody
10/21/2010US20100267620 Methods for slowing senescence and treating and preventing diseases associated with senescence
10/21/2010US20100267618 Methods for treating congestive heart failure
10/21/2010US20100267617 Methods and compositions for mycoplasma pneumoniae exotoxins
10/21/2010US20100267121 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
10/21/2010US20100267045 Cudr as biomarker for cancer progression and therapeutic response
10/21/2010US20100267027 Her-2 binding antagonists
10/21/2010US20100266698 Use of insulin for the treatment of cartilaginous disorders
10/21/2010US20100266686 Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
10/21/2010US20100266680 Treatment of Cancer Using TLR3 Agonists
10/21/2010US20100266674 L-oddc prodrugs for cancer
10/21/2010US20100266672 Vaccines
10/21/2010US20100266668 Manufacturing Dissolvable Dosage Forms
10/21/2010US20100266664 Devices And Methods For Ophthalmic Drug Delivery
10/21/2010US20100266642 Modified cells for targeted cell trafficking and uses thereof
10/21/2010US20100266641 Endophytic Fungi from Pteromischum Sp. Plant, Compounds and Methods of Use
10/21/2010US20100266640 Plant-Derived Cholera and Malaria Vaccine
10/21/2010US20100266639 Expression system
10/21/2010US20100266638 Headache treatment method
10/21/2010US20100266637 Method of preventing early lawsonia intracellularis infections
10/21/2010US20100266636 Method of conferring a protective immune response to norovirus
10/21/2010US20100266635 Hivcon: an hiv immunogen and uses thereof
10/21/2010US20100266634 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
10/21/2010US20100266633 Aids virus vaccines using sendai virus vector
10/21/2010US20100266632 Vaccine composition comprising an immunoadjuvant compound consisting of a rho gtpase family activator
10/21/2010US20100266631 Compositions and Methods for Generating an Immune Response Utilizing Alphavirus-Based Vector Systems
10/21/2010US20100266630 Recombinant MVA virus, and the use thereof
10/21/2010US20100266629 Cattle Reproductive Disease Vaccines
10/21/2010US20100266628 Macrocyclic lactone combination compositions, vaccines and methods for producing same
10/21/2010US20100266627 Allelic exchange mutagenesis in map
10/21/2010US20100266626 Adjuvanted glucans
10/21/2010US20100266625 Meningococcal and Pneumococcal Conjugate Vaccine and Method of Using Same
10/21/2010US20100266624 Hepatitis-c virus testing
10/21/2010US20100266623 Synthetic, self adjuvanting vaccines
10/21/2010US20100266622 Prevention and treatment of ocular side effects with a cyclosporin
10/21/2010US20100266621 Methods and systems for treating cell proliferation disorders with psoralen derivatives
10/21/2010US20100266620 Immunoconjugates for treatment of infectious diseases
10/21/2010US20100266619 Neutralizing Antibodies and Methods of Use Thereof
10/21/2010US20100266618 Compositions and methods for augmenting activity of oncolytic viruses
10/21/2010US20100266617 Antibodies to human programmed death receptor pd-1
10/21/2010US20100266616 Polypeptides, antibody variable domains and antagonists
10/21/2010US20100266615 D1-1 nucleic acids, polypeptides and related methods
10/21/2010US20100266614 Ultra high affinity neutralizing antibodies
10/21/2010US20100266613 Anti-tnf-alpha antibodies and their uses
10/21/2010US20100266612 Bmp-alk3 antagonists and uses for promoting bone growth
10/21/2010US20100266611 Enhancement of Immune Responses By 4-1BB-Binding Agents
10/21/2010US20100266610 Auto-antibody markers of autoimmune disease
1 ... 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 ... 1823